All experimental procedures conformed to the National Health and Medical Research Council (NHMRC, Australia) guidelines and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. All protocols were approved by the Animal Ethical Review Committee of the University of Sydney, Australia.
Reagents were obtained from the following sources: recombinant human FGF-2 and EGF (R&D Systems, Minneapolis, MN); recombinant human IGF-1 (Gropep, Thebarton, SA, Australia); recombinant human PDGF-A (Peprotech, Rocky Hill, NJ); sheep anti-rabbit IgG-HRP-conjugated antibody, mouse anti-phospho-ERK1/2 (pERK1/2; Thr202/Tyr204) antibody, rabbit anti-phospho-Akt (pAkt, Ser473) antibody, and rabbit anti-ERK1/2 antibody (p44/p42 MAP kinase; Cell Signaling Technology, Beverly, MA); bisbenzimide (Hoechst dye, Calbiochem, San Diego, CA); goat anti-mouse IgG-HRP-conjugated (Zymed, South San Francisco CA); goat anti-rabbit IgG conjugated with fluorescein-isothiocyanate (FITC; Sigma-Aldrich, Castle Hill, NSW, Australia); a protein assay kit (Micro BCA; Pierce Biotechnology/Thermo Scientific, Sydney, NSW, Australia); and RTK inhibitors SU5402, AG1296, AG1024, and PD153035 (Calbiochem, La Jolla, CA).